Crinetics Pharmaceuticals, Inc. (CRNX)
Stock Price:
$13.94 USD
-0.66 (-4.52%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
458.40M |
| Revenue (ttm) |
897,000 |
| Net Income (ttm) |
-62.83M |
| Shares Out |
32.88M |
| EPS (ttm) |
-2.41 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$13.94 |
| Previous Close |
$14.60 |
| Change ($) |
-0.66 |
| Change (%) |
-4.52% |
| Day's Open |
14.60 |
| Day's Range |
13.54 - 14.91 |
| Day's Volume |
171,131 |
| 52-Week Range |
10.63 - 26.67 |
More Stats
| Market Cap |
458.40M |
| Enterprise Value |
257.18M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
32.88M |
| Float |
24.29M |
| EPS (basic) |
-2.44 |
| EPS (diluted) |
-2.41 |
| FCF / Share |
-1.76 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.42M |
| Short Ratio |
15.97 |
| Short % of Float |
5.83% |
| Beta |
1.16 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
511.03 |
| PB Ratio |
2.37 |
| Revenue |
897,000 |
| Operating Income |
-65.15M |
| Net Income |
-62.83M |
| Free Cash Flow |
-55.24M |
| Net Cash |
201.22M |
| Net Cash / Share |
6.12 |
| Gross Margin |
-4,494.20% |
| Operating Margin |
-7,263.55% |
| Profit Margin |
-7,004.50% |
| FCF Margin |
-6,158.19% |
| ROA |
-21.88% |
| ROE |
-36.44% |
| ROIC |
-91.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
4 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$34.00*
(143.90% upside)
Low
23.0
Current: $13.94
High
40.0
Target: 34.00
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 1.19 | 2.43 | 2.05 | 0.59 |
| Revenue Growth | -50.86% | 18.73% | 247.2% | - |
| Gross Profit | 1.19 | 2.43 | 2.05 | 0.59 |
| Operating Income | -53.83 | -28.71 | -9.13 | -6.04 |
| Net Income | -50.42 | -27.12 | -9.16 | -6.02 |
| Shares Outstanding | 24.18 | 12.14 | 1.37 | 1.01 |
| Earnings Per Share | -2.09 | -2.23 | -6.68 | -5.96 |
| Operating Cash Flow | -46.38 | -19.46 | -9.48 | -5.47 |
| Capital Expenditures | -0.49 | -1.06 | -0.30 | -0.19 |
| Free Cash Flow | -46.87 | -20.52 | -9.78 | -5.66 |
| Cash & Equivalents | 119 | 164 | 14.19 | 12.15 |
| Total Debt | 4.85 | - | - | 0.21 |
| Net Cash / Debt | 114 | 164 | 14.19 | 11.94 |
| Assets | 130 | 171 | 15.60 | 12.60 |
| Liabilities | 13.24 | 11.19 | 0.92 | 18.80 |
| Book Value | 117 | 160 | -15.02 | -6.20 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Crinetics Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
68 |
| CEO |
Scott R. Struthers |
Stock Information
| Ticker Symbol |
CRNX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CRNX |
| IPO Date |
July 18, 2018 |
Description
Crinetics Pharmaceuticals, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.